Oct
27
2025
10:00
Knee Pain and Hyaluronic Acid: Why High-Molecular-Weight Injections Deliver the Best Results
In the treatment of knee osteoarthritis, hyaluronic acid (HA) injections are being used with increasing frequency to improve joint “lubrication” and function. The summary below explains why high–molecular-weight HA formulations may outperform lower–molecular-weight alternatives and outlines the results that support this, based on the latest research.
The Role of Hyaluronic Acid Injections in the Treatment of Knee Osteoarthritis
Knee osteoarthritis (OA) is one of the most common musculoskeletal disorders. In addition to the gradual degradation of cartilage tissue, the lubricating and shock-absorbing properties of the synovial fluid also deteriorate. Hyaluronic acid (HA) — a key component of this joint fluid — decreases both in concentration and molecular weight as the disease progresses.
Intra-articular (IA-HA) hyaluronic acid injections, also known as viscosupplementation, aim to restore this deficit and improve joint function.
Recent studies have shown that the molecular weight of the HA preparation plays a crucial role: high–molecular-weight (HMW) formulations may provide superior clinical outcomes compared with low–molecular-weight (LMW) alternatives in the management of knee OA.
Why Does Molecular Weight Matter?
Under normal conditions, hyaluronic acid is a fundamental component of the synovial fluid, providing lubrication, reducing friction, and absorbing mechanical shocks within the joint. A reduction in molecular weight—common in OA—impairs these properties. HMW-HA demonstrates longer residence time, better viscoelastic behavior, and often more durable clinical efficacy than lower–molecular-weight forms.
Comparison Between HMW and LMW Hyaluronic Acid
Research indicates that not only the injected amount but also the molecular weight of hyaluronic acid determines treatment outcomes. High–molecular-weight (HMW) forms more closely mimic the properties of healthy synovial fluid and deliver longer-lasting effects than low–molecular-weight (LMW) counterparts.
| Property | HMW-HA (High Molecular Weight) | LMW-HA (Low Molecular Weight) |
|---|---|---|
| Molecular weight | ≥ 1.6 MDa (up to 6,000–7,000 kDa) | < 1.6 MDa |
| Intra-articular persistence | Remains longer in synovial fluid | Degrades more rapidly |
| Viscoelastic properties | Superior lubrication and shock absorption | Weaker mechanical effect |
| Clinical effect (pain, function) | More pronounced and longer-lasting improvement | Often shorter-lived effect |
| Dosage | Single injection often sufficient | Multiple sessions required |
| Safety | Well tolerated, rare side effects | Also safe, but involves more injections |
| Cost-effectiveness | Fewer sessions, longer effect → more economical | More sessions → overall higher cost |
Note: The molecular weight of hyaluronic acid is expressed in MDa (megadaltons), representing polymer chain length. A higher value generally correlates with longer duration of effect.
Therefore, the use of HMW hyaluronic acid can often result in improved quality of life and a more convenient treatment schedule.
Clinical and Meta-Analytic Evidence
The table below summarizes randomized controlled trials (RCTs) and meta-analyses comparing hyaluronic acid formulations of different molecular weights.
| Year | Type | Study design / product | Participants (~) | Main outcome | Notes |
|---|---|---|---|---|---|
| 2019 | RCT | HMW-HA vs. standard care (52 w) (Hermans J et al.) | ~156 | More responders in the HMW group (OMERACT–OARSI criteria) [1] | HMW ≥ 1.6 MDa category |
| 2020 | RCT | Single HMW-HA injection vs. triple LMW-HA (Bahrami MH et al.) | ~90 | Single HMW-HA equally effective at 2–6 months as triple LMW [2] | Head-to-head MW comparison |
| 2006 | RCT | Two HMW-HA formulations – knee OA (Kirchner M et al.) | (not specified) | Pain and function improved with both HMW products [3] | Double-blind trial |
| 1993 | RCT | Sodium hyaluronate (Hyalectin, HMW) intra-articular | (historical data) | Short- and long-term benefits in knee OA [4] | Early clinical trial |
| 2020 | Meta-analysis | HMW-HA vs. LMW-HA (Hummer CD et al.) | Pooled RCTs | HMW-HA met MCII pain/function threshold; LMW did not [5] | MW-stratified analysis |
| — | Narrative / Review | HMW-HA vs. LMW (Webner D et al.) | Multiple formulations compared | HMW-HA provided pain relief lasting ~20 weeks [6] | Summary analysis |
| — | Comparative analysis | HMW-HA vs. LMW-HA (Zhao H et al.) | — | HMW showed advantage at 2–3 months, no increase in AE risk [7] | Limited dataset |
| — | Classical meta-analysis | General IA-HA evaluation (Lo GH et al.) | — | IA-HA overall improved pain and function [8] | Not MW-specific |
Abbreviations: OA – osteoarthritis; HA – hyaluronic acid; HMW / LMW – high / low molecular weight; IA-HA – intra-articular hyaluronic acid; RCT – randomized controlled trial; AE – adverse event; MCII – minimal clinically important improvement; OMERACT–OARSI – international OA response criteria.
Note: “HMW” categorization varies by study (e.g. ≥1.6 MDa or ≥6000 kDa); efficacy depends strongly on protocol and product used.
Detailed Analysis of Clinical Trials and Meta-Analyses
[1] Hermans J et al., 2019 – BMC Musculoskelet Disord. In a 52-week randomized controlled study involving 156 patients with knee OA, intra-articular HMW-HA significantly increased the proportion of responders according to OMERACT–OARSI criteria (57% vs. 34%, p = 0.006). Improvements in pain and function persisted throughout follow-up.
[2] Bahrami MH et al., 2020 – BMC Musculoskelet Disord. This double-blind randomized trial compared a single HMW-HA injection to three LMW-HA treatments. At 2 and 6 months, the single HMW injection proved equally effective in reducing pain and improving function, with low adverse event rates in both groups.
[3] Kirchner M & Marshall D, 2006 – Osteoarthritis Cartilage. A multicenter double-blind RCT compared two HMW-HA formulations in knee OA. Both demonstrated significant pain and function improvements versus placebo, confirming the sustained efficacy of HMW preparations.
[4] Dougados M et al., 1993 – Clin Exp Rheumatol. One of the earliest placebo-controlled trials (110 patients) assessing HMW sodium hyaluronate (Hyalectin) intra-articularly in knee OA. Both short- and long-term benefits were observed in pain reduction and functional improvement.
[5] Hummer CD et al., 2020 – BMC Musculoskelet Disord. This network meta-analysis integrated dozens of RCTs comparing HA formulations of different molecular weights. HMW-HA met MCII thresholds for pain and function, whereas LMW formulations did not, highlighting the importance of MW stratification in efficacy assessment.
[6] Webner D & Naidoo P, 2021 – Cartilage. This review compared multiple viscoelastic HA preparations, emphasizing Hylan G-F 20 as a high–molecular-weight reference. The authors reported that HMW-HA can provide pain relief lasting up to 20 weeks and superior functional outcomes.
[7] Zhao H et al., 2016 – Am J Sports Med. A systematic review and meta-analysis comparing intra-articular HA of varying molecular weights in knee OA found significantly greater pain reduction with HMW-HA at 2–3 months without increased adverse events, supporting higher efficacy at comparable safety.
[8] Lo GH et al., 2003 – JAMA. A landmark meta-analysis of 22 RCTs demonstrated significant pain and functional improvements with IA-HA versus placebo. Although MW-specific differences were not yet analyzed, this study established viscosupplementation as an effective OA treatment.
Interpretation of Results
- HMW-HA injections consistently demonstrate superior clinical outcomes in knee OA regarding both pain and function [1], [5].
- Some studies suggest a single HMW injection may be as effective as multiple LMW injections [2], offering advantages in cost and patient convenience.
- Molecular weight is a key determinant: meta-analyses indicate that without MW stratification, overall IA-HA efficacy may be underestimated [5].
- No significant increase in adverse events was observed in HMW groups, indicating greater efficacy without higher risk [2], [5].
- Optimal outcomes are typically achieved when treatment is administered according to specialist protocol and before advanced-stage OA develops.
Practical Implications
When selecting an IA-HA injection for knee OA, it is advisable to choose a formulation containing high–molecular-weight hyaluronic acid supported by clinical evidence.
Administration should always be performed under medical supervision with appropriate indications, while patient communication should emphasize both benefits (longer duration, fewer sessions) and limitations (may not replace surgery in all cases).
Treatment should form part of a comprehensive musculoskeletal rehabilitation plan, including physiotherapy, weight management, and exercise therapy, as injections alone may not be sufficient.
For some patients, a single HMW injection may provide an efficient, cost-effective solution, though this should be determined individually by the treating physician.
In a randomized, controlled trial involving 156 patients, Hermans and colleagues (2019) demonstrated that intra-articular high–molecular-weight hyaluronic acid (HMW-HA) was significantly more effective at alleviating symptoms of knee osteoarthritis than standard care alone. Over 52 weeks of follow-up, a substantially higher proportion of participants in the HMW-HA group reached the OMERACT–OARSI clinical response threshold (57% vs. 34%, p = 0.006), with superior trajectories for both pain and functional scores.
Summary
Based on the available evidence, intra-articular injections containing high–molecular-weight hyaluronic acid (HMW-HA) appear to be more effective and longer-acting than low–molecular-weight (LMW) formulations for knee osteoarthritis (OA). HMW-HA more closely replicates the viscoelastic properties of healthy synovial fluid, persists longer within the joint space, and delivers more sustained improvements in pain and function in clinical trials.
Randomized controlled trials and meta-analyses consistently show that HMW-HA increases clinical response rates and reduces pain compared with placebo or lower-MW alternatives, while maintaining a low incidence of adverse events. Some studies indicate that a single HMW-HA injection can be at least as effective as multiple LMW treatments, potentially improving convenience and cost-effectiveness.
Therapeutic outcomes are influenced by factors such as OA stage and adjunctive interventions (physiotherapy, weight reduction, exercise therapy). HMW-HA is particularly suitable for patients who are not yet in an advanced disease stage and for whom the goal is to improve quality of life and function without surgery.
Overall, HMW-HA injections represent an effective, safe, and well-tolerated conservative option for knee OA. When appropriately indicated, they can provide meaningful improvements in quality of life and therefore belong among modern, evidence-based nonsurgical treatments for knee osteoarthritis.
References
- Hermans J, Bierma-Zeinstra SMA, Bos PK, Niesten DD, Verhaar JAN, Reijman M. The effectiveness of high molecular weight hyaluronic acid for knee osteoarthritis in patients in the working age: a randomised controlled trial. BMC Musculoskelet Disord. 2019 May 7;20(1):196. doi:10.1186/s12891-019-2546-8. PMID:31064359
- Bahrami MH, Raeissadat SA, Cheraghi M, Rahimi-Dehgolan S, Ebrahimpour A. Efficacy of single high-molecular-weight versus triple low-molecular-weight intra-articular hyaluronic acid in knee osteoarthritis patients. BMC Musculoskelet Disord. 2020 Aug 15;21(1):550. doi:10.1186/s12891-020-03577-8. PMID: 32799851.
- Kirchner M., Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006 Feb;14(2):154-162. doi:10.1016/j.joca.2005.09.003. PMID:16242361.
- Dougados M, Büttner M, et al. High molecular weight sodium hyaluronate (Hyalectin) in intra-articular treatment of knee osteoarthritis: a randomized, placebo-controlled trial in 110 patients. Clin Exp Rheumatol. 1993;11(5):595-602. doi: (–). PMID: 8886085.
- Hummer C D, Angst F, Ngai W, Whittington C, Yoon S S, Duarte L, Manitt C, Schemitsch E. High molecular weight intra-articular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis. BMC Musculoskelet Disord. 2020;21(1):702. doi:10.1186/s12891-020-03729-w. PMID:33097031.
- Webner D, Naidoo P. Intra-articular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others? Cartilage. 2021 Dec;13(1_suppl):1619S-1636S. doi:10.1177/19476035211017320. PMID: 34044600.
- Zhao H, et al. Comparison of different molecular weights of intra-articular hyaluronic acid injections for knee osteoarthritis: a systematic review and meta-analysis. Am J Sports Med. 2016;44(4):1028–1039. PMID: 27435213
- Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA. 2003 Dec 17; 290(23): 3115-3121. doi: 10.1001/jama.290.23.3115. PMID: 14679274.